Lung Cancer

Dr. Aggarwal and Dr. Girard discuss the significance of the 5-year survival data from the pivotal PACIFIC trial and the real-world benefit of the study regimen in patients with unresectable stage III non–small cell lung cancer.

Optellum and the Lung Cancer Initiative at Johnson & Johnson plan to use Optellum’s artificial intelligence-based decision support software in an effort to increase lung cancer survival rates via disease prevention and early intervention.

Alexander I. Spira, MD, PhD, FACP, discusses the impact of the PACIFIC-R trial in patients with unresectable stage III non–small cell lung cancer.

Bob T. Li, MD, PhD, MPH, discusses the results of the phase 2 DESTINY-Lung01 trial in HER2-positive metastatic non–small cell lung cancer.

The availability of targeted agents for patients with advanced non–small cell lung cancer who harbor mutations in EGFR, RET, MET, and KRAS has not only led to improved outcomes, but provided greater flexibility for treatment-naïve and pretreated populations, with the possibility of enhanced intracranial activity.

The achievements of Roman Perez-Soler, MD, include studies of anti-EGFR therapies and topoisomerase inhibitors, extensive research on liposomal delivery systems, and early work on patient-derived xenografts in mice.

The addition of bevacizumab to erlotinib continued to provide a significant progression-free survival benefit over erlotinib alone when used in the frontline treatment of patients with EGFR-mutated, nonsquamous non–small cell lung cancer, according to data from the final analysis of the phase 3 BEVERLY trial.

The median real-world progression-free survival with durvalumab was higher compared with the median progression-free survival reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.

The addition of durvalumab to platinum/etoposide chemotherapy continued to demonstrate an overall survival benefit over chemotherapy alone with a favorable safety profile in patients with extensive-stage small cell lung cancer.

Sitravatinib, a spectrum-selective TKI targeting TAM receptors and VEGFR2, administered in combination with nivolumab induced durable response and robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

Blood-based tumor mutational burden does not predict a benefit of first-line atezolizumab over chemotherapy in patients with non–small cell lung cancer.

Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer. 

Dr. Dietrich discusses the latest developments with immunotherapy and targeted therapy in stage III non–small cell lung cancer.

Adjuvant treatment with atezolizumab led to an improvement in disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of PD-L1–positive patients with stage II to IIIA NSCLC, according to exploratory findings from the phase 3 IMpower010 trial.

Marina Garassino, MD, discusses the results of subgroup analyses of the phase 2 VISION trial in MET exon 14 skipping mutation–positive non-small cell lung cancer.

Poziotinib, administered once daily at 16 mg, induced a median tumor reduction of 35% in patients with treatment-naïve non–small cell lung cancer harboring HER2 exon 20 mutations, according to findings from cohort 4 of the ongoing phase 2 ZENITH20 trial.

The frontline combination of nivolumab and ipilimumab continued to demonstrate improved overall survival across subgroups compared with standard chemotherapy at 3 years in patients with unresectable malignant pleural mesothelioma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pralsetinib for use as a single agent in adult patients with RET fusion–positive advanced non–small cell lung cancer who did not receive prior RET inhibition.

Brigatinib resulted in a 52% reduction in the risk of disease progression or death and a 56% reduction in the risk of intracranial progression compared with crizotinib in patients with ALK-positive non–small cell lung cancer, according to final data from the phase 3 ALTA-1L trial.

Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts in Japanese patients with non–small cell lung cancer, which, when coupled with pharmacokinetic analysis, led to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in this population.

Mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy when compared indirectly with real-world data of patients treated with standard of care.

Estelamari Rodriguez, MD, MPH, discusses the role of immunotherapy in extensive-stage small cell lung cancer.

Collin Blakely MD, PhD, discusses the design of an ongoing phase 2 trial examining osimertinib in resectable EGFR-mutant non–small cell lung cancer.

The FDA has approved mobocertinib for the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer with EGFR exon 20 insertion mutations as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Chad V. Pecot, MD, discusses selecting between available targeted therapies in RET-, KRAS-, and MET exon 14 skipping–mutant non–small cell lung cancer.